BCTX Stock — Briacell Therapeutics Corp

Briacell Therapeutics Corp (BCTX)

Updated October 16, 2026.

BCTX is a Stock. Its deepest 1-year drawdown was 80.1%.

BriaCell Therapeutics is a pre-clinical stage immuno-oncology company developing targeted immunotherapies for cancer treatment, with its lead candidate Bria-IMT in Phase 3 clinical trials for end-stage breast cancer, alongside programs in personalized off-the-shelf immunotherapy and soluble CD80 protein therapeutics. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotech development with potential for significant capital appreciation, rather than those seeking current income.

BCTX performance

Returns are updating. BCTX's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 80.1%.

BCTX key facts

Asset type

Stock

Asset class

Equity

Inception date

04/16/2012

Distribution frequency

None

Last close

$3.40 (as of 2026-10-16)

Market cap

$29,579,276

Average volume

134004.0

Payment date

01/02/2020

Beta

1.506

Payout ratio

0.0%

EPS

$-0.92

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BCTX risks and drawbacks

The deepest 1-year drawdown on record here is 80.1%.

Who may consider BCTX — and who may not

It is a weaker fit for investors who need monthly cash flow (BCTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BCTX

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions